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Abstract 26 
Obesity causes dysfunction of adipose tissue, with resultant chronic inflammation and 27 
adverse interplay of various adipokines, sex steroids and endocrine hormones. All 28 
these drive tumourigenesis and explain the epidemiological link between obesity and 29 
cancer. Over the past decade, the associations among obesity, adipokines and cancer 30 
have been increasingly recognized. Adipokines and their respective signaling 31 
pathways have drawn much research attention in the field of oncology and cancer 32 
therapeutics. This review will discuss the recent advances in the understanding of the 33 
association of several adipokines with common obesity-related cancers, and the 34 
clinical therapeutic implications. 35 
 36 
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Introduction 51 
 52 
Tackling obesity is a growing challenge. The increasing prevalence of obesity 53 
worldwide does not just propel the upsurge of incident diabetes, metabolic syndrome 54 
and cardiovascular diseases, but also of incident cancers. A meta-analysis, involving 55 
282137 incident cases from prospective observational studies, had shown that 56 
increased body mass index (BMI) was associated with a higher risk of both common 57 
and less common cancers. (1) Increased risks of incident cancers by 6 to 59%, 58 
involving oesophageal adenocarcinoma, leukaemia, non-Hodgkin lymphoma, colon, 59 
thyroid and renal cancers, were associated with every increment of 5 kg/m2 in BMI 60 
above normal in both sexes. In men, significant positive associations were also noted 61 
with rectal cancer and malignant melanoma. In women, positive associations were 62 
found with endometrial, gallbladder, pancreatic and post-menopausal breast cancers 63 
as well. (1) In fact, Calle et al had estimated that in the United States, obesity 64 
contributed to 14% of all cancer mortality in men and 20% of those in women. (2) In 65 
UK, a recent population-based cohort study involving 166955 subjects with cancer, 66 
suggested that BMI was associated with 17 out of 22 cancers studied. Furthermore, it 67 
also estimated that every unit of population-wide increment in BMI would lead to an 68 
addition of 3790 UK subjects developing one of the ten common obesity-related 69 
cancers annually. (3) In Asian-Pacific populations, a meta-analysis also showed that 70 
every increment of 5 units in BMI above 18.5 kg/m2 was associated with an increase 71 
in cancer mortality by 1.09 for all cancers. (4) In Chinese, although the overall 72 
prevalence of obesity is lower than the west, even when Asian-Pacific BMI cut-offs 73 
are used (5), obesity has also been demonstrated as an independent predictor of 74 
incident cancers. In a community-based cohort of 2895 Hong Kong Chinese subjects 75 
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aged 25 to 74 recruited from the general population, over a median follow-up of 16 76 
years, 209 (7.2%) of them developed cancers. Baseline waist circumference, an 77 
indicator of central adiposity, independently predicted incident cancers with a 78 
standardized odds ratio of 1.19 (95% CI 1.02 – 1.40; p = 0.031) even after adjustment 79 
for age of subjects. (6) All these suggested that the association between obesity and 80 
cancer was consistent across populations worldwide. In fact, in Asian-Pacific 81 
populations, the association between increased BMI and breast cancer was even 82 
stronger, in both pre- and post-menopausal women, than in populations of North 83 
America, Europe and Australia. (1) Recent meta-analyses also suggested that both 84 
pre- and post-menopausal breast cancer patients who were obese had poorer overall 85 
survival regardless of when BMI was ascertained. (7) Furthermore, in men, obesity 86 
increased the risk of prostate cancer specific mortality as well as biochemical 87 
recurrence. (8) Taken together, cumulative epidemiological evidence would suggest 88 
that overweight or obese subjects are not just at increased risk of cancer development: 89 
in those who have developed cancers, obese patients also tend to have worse 90 
prognosis. 91 
 92 
Preclinical studies have provided insights into the pathogenic mechanisms linking 93 
obesity and cancer. While several molecular pathways have been proposed, all of 94 
them actually stem from a dysfunctional adipose tissue, with ultimate creation of a 95 
microenvironment that favours tumour development. (9, 10) In obesity, coupled with 96 
the expansion in adipose tissue mass are increases in tissue hypoxia, inflammation 97 
and insulin resistance. Furthermore, the delicate interplay among obesity-associated 98 
sex hormones, insulin growth factor 1 (IGF1) and the various adipokines further 99 
contributes to enhanced inflammatory signaling, angiogenesis, cellular proliferation 100 
Page 4 of 30Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
and ultimately, carcinogenesis. In this review, we will focus on the role of adipokines 101 
in the development of various cancers in the context of obesity. 102 
 103 
Adipokines in obesity-related cancer development 104 
 105 
The adipose tissue is a complex, highly active endocrine organ. It is integrally 106 
involved in carcinogenesis via dysregulated secretion of various adipokines, which 107 
are polypeptide cytokines produced by white adipose tissue, either exclusively or 108 
substantially, and can act both locally and systemically. (11, 12) These adipokines 109 
have been implicated in cancer development and progression through their effects on 110 
insulin resistance, lipolysis and various inflammatory pathways. (9) In the context of 111 
obesity, the hypertrophic expansion of adipose tissue induces local hypoxia, 112 
inflammatory activation and reactive angiogenesis, changes which favour 113 
tumourigenesis. Some of the proinflammatory adipokines, such as interleukin-6 (IL-6) 114 
and leptin, have been shown to stimulate cancer stem cells, which are stromal cells 115 
with tumourigenic potential, leading to increased tumour growth and survival. (10) On 116 
the other hand, cancer cells are known to stimulate lipolysis in the cancer-associated 117 
adipocytes, the delipidation of which is followed by their differentiation to a 118 
fibroblast-like phenotype with increased secretion of proinflammatory cytokines such 119 
as IL-6 and plasminogen activator inhibitor-1 (PAI-1). (10) Thus the interaction of the 120 
cancer-associated adipocytes with their neighbouring cancer cells creates a tumour 121 
permissive microenvironment which would support cancer growth, progression and 122 
metastases. (10) 123 
 124 
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To date, more than 15 adipokines have been reported in the literature to be associated 125 
with cancers and this list is still growing. (11, 13) While the circulating levels of 126 
majority of pro-inflammatory adipokine levels, like leptin (Table 1), IL-6 and tumour 127 
necrosis factor alpha (TNF-α), are increased in cancers, some adipokines like 128 
adiponectin are protective against tumourigenesis and its serum levels are usually 129 
decreased in the cancer patients. (11) (Table 1) We previously demonstrated that, in a 130 
Chinese community cohort in Hong Kong, subjects who developed cancers also had 131 
higher baseline levels of C-reactive protein, IL-6, soluble tumour necrosis factor 132 
receptor 2 (a surrogate marker of TNF-α activity) and lipocalin 2. (6) 133 
 134 
New insights into the role of specific adipokine in various obesity-related cancers 135 
 136 
Adiponectin 137 
Adiponectin is one of the most abundant adipokines secreted by adipocytes. It is 138 
secreted into the circulation as three oligomeric complexes, including trimer, 139 
hexamer, and high molecular weight (HMW) multimer. Among them, HMW 140 
adiponectin is the major active form mediating the insulin sensitizing effect of this 141 
adipokine. (14) Adiponectin has been shown to modulate the biological actions of 142 
several growth factors, including platelet-derived growth factor BB, basic fibroblast 143 
growth factor, and heparin-binding epidermal growth factor-like growth factor, 144 
through specific binding of these growth factors in an oligomerization dependent 145 
manner, with HMW adiponectin being able to bind all three growth factors. (15) 146 
These in vitro findings suggest that adiponectin, especially HMW adiponectin, can 147 
exert its anti-proliferative action by reducing the bioavailability of these growth 148 
factors at a pre-receptor level. The biosynthesis and secretion of these oligomers by 149 
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adipocytes are tightly controlled by molecular chaperones in the endoplasmic 150 
reticulum. (14) In the context of obesity, both the intracellular assembly and the 151 
secretion of the HMW adiponectin are impaired. (14) The resultant 152 
hypoadiponectinaemia in obesity both directly and indirectly promotes 153 
carcinogenesis. Adiponectin acts through two main receptors AdipoR1 and AdipoR2, 154 
both of which were reported to be expressed in several cancer cells in vitro and in 155 
vivo. (9, 16) Binding of adiponectin to these receptors impact on downstream 156 
signaling pathways (Figure 1) including the activation of AMP-activated protein 157 
kinase (AMPK) and ceramidase activities, and the inhibition of phosphatidylinositol 158 
3-kinase, wingless type protein (Wnt) / β-catenin, extracellular regulated kinase 1 or 2 159 
(ERK1/2), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, signal 160 
transducer and activator of transcription (STAT3), and nuclear factor κB (NF-κB). 161 
(16) Furthermore, there are emerging data on the role of T-cadherin, an adiponectin-162 
binding protein, which docks adiponectin to responsive tissues, as demonstrated in the 163 
heart, muscle and vasculature(17).  While both in vivo and in vitro studies had shown 164 
that T-cadherin inhibited tumour cell proliferation and invasiveness(18), there have 165 
also been a few studies suggesting that it may promote tumour angiogenesis. (17) 166 
Nevertheless, hypoadiponectinaemia in general increases fatty acid and protein 167 
synthesis (and hence promotes cell growth), proliferation, and DNA-mutagenesis, and 168 
inhibits cell cycle arrest and apoptosis. (16) Furthermore, hypoadiponectinaemia also 169 
indirectly affects tumorigenesis via several mechanisms. Firstly, insulin resistance is 170 
increased, with resultant elevation in insulin and bioavailable IGF1 levels, which 171 
enhance tumour cellular proliferation. Secondly, as adipocytes constitute one of the 172 
predominant stromal cell types in the tumour microenvironment, adiponectin could 173 
act as a stromal factor that helps balance the local redox and metabolism. (19) Finally, 174 
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hypoadiponectinaemia exerts pro-inflammatory effects via enhancing the production 175 
of various proinflammatory cytokines including TNF-α and IL-6, further contributing 176 
to the tumour permissive microenvironment that facilitates tumourigenesis. (9, 10)  177 
 178 
Adiponectin and breast cancer 179 
The association between adiponectin and breast cancer risk depends on menopausal 180 
status. Conflicting data have been reported regarding the association in pre-181 
menopausal women. Macis et al. reported that low serum adiponectin levels predicted 182 
incident breast neoplastic events independently of age and BMI in pre-menopausal 183 
women (20). However, in a recent meta-analysis involving 4249 breast cancer cases 184 
and including those studied by Macis et al (20), the inverse association between serum 185 
adiponectin level and breast cancer risk did not reach statistical significance in 186 
premenopausal women (relative risk 0.72; 95% CI 0.30 – 1.72) (21). On the other 187 
hand, two large meta-analyses demonstrated clearly a consistent inverse association in 188 
post-menopausal women (21-23), with every increment of 3ug/ml in adiponectin level 189 
corresponding to a 5% risk reduction in post-menopausal breast cancer. (21)  190 
 191 
Breast cancer is one of the most common hormone-dependent cancers, and its positive 192 
correlation with obesity, especially in post-menopausal women, is explained, at least 193 
in part, by the increase in aromatase activity in the expanded adipocyte tissue. On the 194 
other hand, in vitro studies from our group had demonstrated that, adiponectin 195 
inhibited cell proliferation and induced apoptosis of human breast cancer cell-lines, 196 
independent of the presence of the estrogen receptor. (19, 24) Furthermore, in 197 
MMTV-polyomavirus middle T antigen (MMTV-PyVT) transgenic mice with 198 
reduced adiponectin expressions, hypoadiponectinaemia promoted mammary 199 
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tumourigenesis by down-regulation of phosphatase and tensin homolog (PTEN) 200 
activity. (25) In addition, treatment with recombinant adiponectin reduced mammary 201 
tumourigenesis in nude mice through suppressing the Wnt / glycogen synthase kinase 202 
(GSK)-3β / β-catenin pathway. Increased β-catenin activity correlated significantly 203 
with worse prognosis. (24) These preclinical data have provided mechanistic insight 204 
on the association between hypoadiponectinaemia and biologically aggressive tumour 205 
phenotype observed in patients with breast cancer. (26) 206 
 207 
Adiponectin and prostate cancer 208 
In vitro studies demonstrated that adiponectin down-regulated STAT3 signaling and 209 
inhibited cell growth and proliferation of both androgen independent and androgen 210 
dependent metastatic prostatic cancer cells. (27) However, the association between 211 
adiponectin and prostate cancer remains inconclusive, partly due to the scarcity of 212 
data. (28) While some evidence suggested that adiponectin was not related to overall 213 
prostate cancer risk, there were also data showing that patients with 214 
hypoadiponectinaemia suffer from more aggressive, metastatic and fatal prostate 215 
cancer. (16, 27) However, a recent nested case-control cohort did not find such an 216 
association in 272 cases with aggressive prostate cancer. (29)  217 
 218 
Adiponectin and gastrointestinal cancers 219 
Adiponectin has also been implicated in tumourigenesis of various gastrointestinal 220 
cancers. (30) 221 
 222 
Hypoadiponectaemia increased the risk of Barrett’s esophagus, which is more 223 
prevalent in obese individuals and is closely associated with the development of 224 
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esophageal adenocarcinoma. Recently, in vitro studies found that adiponectin could 225 
decrease the invasion and migration of esophageal cancer cell lines OE33 via the 226 
activation of protein tyrosine phosphatase 1B and, consequently, the inhibition of 227 
leptin-induced janus kinase (JAK) signaling. (31) In gastric cancer, adiponectin 228 
receptor AdipoR1 expression was associated with a better disease prognosis. Firstly, 229 
negative immunostaining for adipoR1 in tumour cells was significantly higher in 230 
patients with lymphatic metastases. Secondly, survival analysis revealed a longer 231 
survival in those with positive adipoR1 expression. (32) In hepatocellular carcinoma, 232 
hypoadiponectinaemia increased the risk of hepatic adenoma formation in animal 233 
studies. When adiponectin-knockout mice were fed a choline-deficient L-amino-acid-234 
defined diet for 24 weeks, they developed more severe non-alcoholic steatohepatitis 235 
and also more liver tumours compared to the wild type mice. (33) Liver cancer 236 
microarray studies also demonstrated an inverse relationship between adiponectin 237 
expression and tumour size, suggesting a role of adiponectin in suppressing the 238 
proliferation and de-differentiation of liver cancer. (34) In pancreatic cancer, in-vitro 239 
studies also suggested the role of adiponectin in suppressing the proliferation of 240 
pancreatic cell lines via its impact on the NF-κB pathway. (30) 241 
 242 
In the context of colorectal cancer, animal studies had shown that mice lacking 243 
adiponectin gene and its receptor, AdipoR1 or AdipoR2 were predisposed to 244 
colorectal polyp formation on high fat diet. (35) Furthermore, it was postulated that 245 
hypoadiponectinaemia led to increased activity of c-Jun N-terminal kinase (JNK), an 246 
oncogene that was abnormally elevated in colorectal cancer. (36) Through signaling 247 
pathways involving AMPK and mammalian target of rapamycin (mTOR), 248 
hypoadiponectinaemia also promoted colorectal cancer cell growth and inhibited 249 
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G1/S cell cycle arrest. (30) A recent meta-analysis demonstrated that an inverse 250 
association between adiponectin and colorectal cancer, among studies with 251 
prospective design (OR 0.716; 95% CI 0.606 – 0.847). (37) 252 
 253 
Adiponectin and other cancers 254 
Previous epidemiological studies showed discrepant results on the association 255 
between adiponectin and endometrial cancer. (27) Some suggested 256 
hypoadiponectaemia increased the risk of endometrial cancer independent of other 257 
conventional risk factors including BMI, especially in those younger than 65 years 258 
old. (16) A recent prospective cohort involving 167 incident endometrial cancer cases 259 
had shown, however, that the association between hypoadiponectaemia and 260 
endometrial cancer risk depended upon the use of menopausal hormonal therapy. 261 
Inverse association between adiponectin and endometrial cancer, which remained 262 
significant even after adjustment for estradiol levels and BMI, was only observed in 263 
women not on menopausal hormonal therapy, suggesting that adiponectin might 264 
influence cancer risk through mechanisms other than estrogen-mediated endometrial 265 
proliferation. (38) In fact, adiponectin might exert its anti-cancer effect via the NF-κB 266 
signaling pathway to suppress vascular endothelial growth factor (VEGF) expression. 267 
(27) Furthermore, in vitro studies also showed its suppression of endometrial cancer 268 
cell proliferation via enhancing the expression of the adaptor molecule LKB1, which 269 
is required for adiponectin-involved activation of AMPK. (39) 270 
 271 
The association between adiponectin and renal cancer remains inconclusive. A recent 272 
case-control study involving 187 cases of renal cell carcinoma has even shown higher 273 
adiponectin levels in renal cell cancer cases. (40) Previous studies suggested that 274 
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AdipoR2 was downregulated in renal cancer tumour tissue, and hence the protective 275 
effect of adiponectin might have also been attenuated. (16, 27) Contrary to the above 276 
findings, it has also been suggested that adiponectin might be employed as a 277 
biomarker for renal cell cancer progression, as both total and high molecular weight 278 
oligomers were demonstrated to be higher in patients with localized disease than those 279 
with metastatic clear cell carcinoma, the commonest subtype of renal cell carcinoma. 280 
(16, 41) 281 
 282 
Differentiated thyroid carcinoma, which included papillary thyroid carcinoma, was 283 
inversely associated with serum adiponectin levels. (42) In addition to the 284 
development of incident thyroid cancer, serum adiponectin levels also had implication 285 
in its prognosis. Patients with papillary thyroid carcinoma were more likely to have 286 
multicentric tumours, or tumours with extrathyroidal invasion and higher TNM stage 287 
if their tumour tissues were negative for both AdipoR1 and AdipoR2 expressions. 288 
(43) 289 
 290 
With regard to haematological malignancies, the associations with adiponectin are 291 
heterogeneous. Inverse associations had been reported between serum adiponectin 292 
levels and risks of incident myelodysplastic syndrome, myeloproliferative disease, 293 
childhood myeloblastic leukaemia, monoclonal gammopathy of undetermined 294 
significance, multiple myeloma and chronic lymphocytic leukaemia. (16) This is in 295 
keeping with the notion that adiponectin inhibited proliferation of cells of myeloid 296 
lineage. Furthermore, adiponectin might prevent myeloma risk by suppressing the 297 
secretion and action of pro-inflammatory cytokines and their activation of the NF-κB 298 
signaling pathway. (44) On the contrary, there had been reports showing that higher 299 
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levels of serum adiponectin were associated with both adult and childhood non-300 
Hodgkin’s lymphoma. (16) It has been postulated such an association may be 301 
explained by the action of adiponectin in enhancing the secretion of interleukin-10 302 
(IL-10), a known growth factor produced by non-Hodgkin’s lymphoma cells. (45) 303 
 304 
Leptin 305 
Leptin, the product of the Obese (OB) gene, is an adipokine primarily secreted by 306 
white adipose tissue. In addition to its key role in energy homeostasis as a satiety 307 
hormone, leptin also exerts other effects in an endocrine fashion. In the context of 308 
obesity, leptin level increases with the expansion of the adipose tissue mass. In 309 
humans, obesity is associated with leptin resistance, further increasing the circulating 310 
leptin level. By binding to its receptors (Ob-R), which are expressed in almost every 311 
tissue, leptin modulates various downstream signaling pathways (Figure 1) including 312 
JAK / STAT3, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-313 
kinase / protein kinase B (PI3K/Akt), ERK1/2, AMPK and insulin receptor substrate 314 
(IRS) pathways. (9, 11) In contrast to the anti-inflammatory actions of adiponectin, 315 
leptin activates inflammatory cell response and induces pro-inflammatory cytokine 316 
production. (46) Furthermore, in vitro studies demonstrated that leptin could induce 317 
endothelial cell proliferation and activate vascular endothelial growth factor (VEGF), 318 
and other proangiogenic factors. (47) These resultant effects make leptin an adipokine 319 
with mitogenic, anti-apoptotic and pro-inflammatory properties, all being implicated 320 
in carcinogenesis. 321 
 322 
Leptin and breast cancer 323 
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As in adiponectin, the association between leptin and breast cancer also seems to 324 
depend on menopausal status. While there is consistent evidence showing that serum 325 
leptin level correlates positively with breast cancer risk in postmenopausal women, an 326 
inverse relationship has been reported in premenopausal subjects. (27, 48, 49) 327 
Nonetheless, previous in vitro studies had already demonstrated that leptin promoted 328 
mammary tumourigenesis via activation of JAK/STAT3 and PI3K signaling 329 
pathways. (50) Leptin has also been shown to affect the prognosis of breast cancer. 330 
Leptin-receptor-positive tumours had higher metastatic potential than those that were 331 
negative for leptin-receptor. (51) A recent study confirmed that leptin stimulated 332 
proliferation of breast cancer cells but not of normal breast cells. In particular, leptin 333 
induced proliferation of estrogen-dependent breast cancer cell lines such as MCF7 334 
and T47D but not of the estrogen-independent breast cancer cell lines MDA-MB-231. 335 
(52) In fact, functional bidirectional crosstalk had been demonstrated between leptin 336 
and estrogen receptors. Leptin could amplify estrogen signaling by activation of 337 
estrogen receptor-α and aromatase gene (CYP192A) expression. Estradiol, on the 338 
other hand, could modulate leptin receptor expression in animal studies and also 339 
induced expression of leptin and its receptor in MCF7 breast cancer cells. (50) The 340 
effect of leptin on estrogen-independent breast cancers, however, has remained 341 
controversial. A study by Colbert et al. in 67 Chinese patients with breast cancer 342 
demonstrated that more than 61% of breast cancer tissues, which included estrogen 343 
receptor positive, estrogen receptor negative and triple (estrogen, progesterone and 344 
HER2 receptors) negative tumours, were stained positive for leptin and its receptor. 345 
Furthermore, leptin and its receptor were positively associated with proangiogenic 346 
factors like Notch and vascular endothelial growth factor (VEGF), and hence 347 
implicated in tumour aggressiveness and poorer prognosis. (53) 348 
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 349 
Leptin and prostate cancer 350 
Data on the association between leptin and prostate cancer has also been conflicting. 351 
Some studies suggested that higher leptin levels were linked to more advanced and 352 
hormone-refractory prostate cancer. (27) In vitro studies demonstrated that leptin 353 
exerted its pro-carcinogenic effects via the activation of PI3K, MAPK and JNK-MAP 354 
kinase pathways. (27) Leptin could induce proliferation, inhibit apoptosis and 355 
promote the migration of androgen-insensitive prostate cell lines DU145 and PC3 but 356 
did not have an effect on the androgen-sensitive cell line LNCaP. (28) 357 
 358 
Leptin and gastrointestinal cancers 359 
Although leptin was linked with colorectal cancer risks in multiple epidemiological 360 
studies, a recent meta-analysis did not observe any significant association between 361 
leptin and colorectal carcinoma. (37) Nonetheless, animal studies had shown that 362 
leptin-deficient mice were less prone to colonic polyp formation upon induction by 363 
azoxymethane or when fed with a high fat diet, when compared to control mice. (54) 364 
Furthermore, leptin could stimulate the proliferation of the human colorectal cancer 365 
cell line HCT-116 via the PI3K-AKT signaling pathway. (10) Recently, leptin was 366 
shown to induce the proliferation of gastric cancer cells through activation of STAT3 367 
and ERK1/2. (55) 368 
 369 
On the contrary, although studies on the association between leptin and pancreatic 370 
cancer are scarce, most of them showed that leptin levels were lower in patients with 371 
pancreatic cancer than in controls. While some had attributed the hypoleptinaemia to 372 
the weight loss that was commonly observed in pancreatic cancer patients (27), a 373 
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recent study suggested that patients with newly diagnosed pancreatic cancer had 374 
significantly lower serum leptin levels and these differences were independent of age 375 
and BMI. (56) In vitro studies also showed that leptin could inhibit human pancreatic 376 
cancer cell lines PANC-1 and Mia-PaCa. (27) 377 
 378 
Leptin and other cancers 379 
A recent prospective cohort study involving 167 incident endometrial cancer cases 380 
demonstrated that, as in the case of adiponectin, the association between leptin and 381 
endometrial cancer risk also depended upon the use of menopausal hormonal therapy. 382 
Leptin was significantly associated with increased risk of endometrial cancer, even 383 
after adjustment for estradiol level and BMI. However, this was only observed in 384 
women not on menopausal hormonal therapy, suggesting that leptin might also 385 
influence cancer risk through mechanisms other than estrogen-mediated endometrial 386 
proliferation. (38) 387 
 388 
The association between leptin and renal cell carcinoma has remained inconclusive 389 
over the years. (27) A recent report observed that higher leptin levels were found in 390 
patients with renal cell carcinoma, which, though attenuated, remained significant 391 
after adjustment for BMI. However, this association was shown to differ by race, as it 392 
was significant in Caucasians but not among African Americans. (40) 393 
 394 
In differentiated thyroid cancers, the expression of leptin and its receptor was 395 
associated with a higher risk of lymph node metastases. (42) Moreover, leptin could 396 
affect the migration of thyroid cells, conferring higher metastatic potential and worse 397 
prognosis. (57) In the context of haematological malignancies, however, no positive 398 
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associations were reported between leptin levels and multiple myeloma or non-399 
Hodgkin lymphoma. (44, 58)  400 
 401 
Recently, there have been more studies looking into the association between leptin 402 
and malignant melanoma. (59, 60) Leptin was found not only to correlate positively 403 
with the risk of developing malignant melanoma, but also accelerate tumour growth. 404 
Interestingly, it has been proposed that serum leptin receptor levels might possibly be 405 
employed as a new tumour marker of malignant melenoma as its levels are inversely 406 
associated with the stage of the disease, with highest levels found at the in situ stage 407 
and lowest at stage IV. (59) 408 
 409 
IL-6, TNF-α and various cancers 410 
Both IL-6 and TNF-α are key cytokines involved in inflammation and immunity. 411 
They are produced and secreted by several cells, including macrophages and 412 
adipocytes. Both M1 and M2 macrophages are present in adipose tissue, but they 413 
differ in the profile of cytokines they produced. In the context of obesity, local tissue 414 
hypoxia around adipocytes promotes the switch of macrophages from M2 to the M1 415 
phenotype. This changes the production profile from anti-inflammatory cytokines like 416 
interleukin-10 of the M2 macrophages to pro-inflammatory cytokines like IL-6 and 417 
TNF-α of the M1 macrophages. (9) Consequently, both the production and secretion 418 
of these two adipokines are increased, and together they enhance tumourigenesis via 419 
their pro-inflammatory effects. IL-6 promotes carcinogenesis mainly through the 420 
JAK/STAT3 signaling pathway, which is involved in tumour proliferation, survival 421 
and angiogenesis. TNF-α, on the other hand, activates the NF-κB and JNK signaling 422 
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pathways. (11) Furthermore, both adipokines can promote carcinogenesis through 423 
enhancing the conversion of non-cancer cells to tumour stem cells. (10) 424 
 425 
Large amount of epidemiological evidence supported the role of IL-6 and TNF-α in 426 
carcinogenesis and its progression. Serum IL-6 was shown to correlate positively with 427 
advanced staging in colorectal, breast and cervical cancers, hepatocellular and renal 428 
cell carcinoma. (61) The IL-6 receptor/STAT3 pathway also contributed to the 429 
pathogenesis of multiple myeloma by protecting the myeloma cells from apoptosis. 430 
(62) Furthermore, it had been reported to be associated with poor prognosis in 431 
esophageal, gastric, colorectal, pancreatic, bladder, breast, ovarian and prostate 432 
cancers, hepatocellular and renal cell carcinoma. (61) Similarly, high levels of 433 
circulating TNF-α were found in patients with lung, pancreatic, breast and prostate 434 
cancers. (63) In differentiated thyroid cancer, however, the exact role of IL-6 remains 435 
to be elucidated. (42) In a Chinese community cohort in Hong Kong with a relatively 436 
low prevalence of obesity, we previously demonstrated central obesity predicted 437 
cancer development, and baseline IL-6 and soluble TNF receptor 2 levels were 438 
independent predictors of incident cancer development after a median interval of 9.5 439 
years, even after adjusting for conventional cancer risk factors. (6) 440 
 441 
Interplay of adipokines in cancers 442 
Although adipokine may individually be involved in the development of various 443 
obesity-related cancers and impact on their progression, there are diverse and complex 444 
interplay via crosstalk with each other through their respective downstream signaling 445 
pathways. (Figure 1)  In fact, the associations between leptin and some cancers are 446 
often related to adiponectin as well. In esophageal cancer, for example, leptin-induced 447 
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proliferation of esophageal adenocarcinoma cell lines could be inhibited by 448 
adiponectin via AdipoR1. (30, 31) Similarly, leptin-induced proliferation of 449 
hepatocellular tumour cells was also inhibited by adiponectin via the STAT3 450 
signaling pathway. (10) 451 
 452 
Other adipokines and cancers 453 
Increasing epidemiological evidence has shown that a number of other adipokines are 454 
also involved in obesity-related cancers. Neutrophil gelatinase-associated lipocalin 455 
(NGAL) or lipocalin-2, for example, was over-expressed in breast, gastric, esophagus 456 
and brain cancers. (11) Recently, lipocalin-2 was also noted to be associated with 457 
tumour invasiveness, possibly attributed to its ability to scavenge iron into cancer 458 
cells. (64) Resistin, another pro-inflammatory adipokine, was found to be present at 459 
higher levels in advanced non-small cell lung, colon, breast and prostate cancers. (11) 460 
A recent meta-analysis also suggested a consistent positive association between 461 
resistin and colorectal cancers, although the number of studies was limited. (37) 462 
 463 
Clinical and therapeutic implications 464 
Owing to the fast growing prevalence of both obesity and cancer worldwide, together 465 
with their associated morbidity and mortality, they have become major global 466 
healthcare concerns. 467 
 468 
Tackling obesity and cancer are equally challenging. It was not until recently that 469 
there was evidence showing that weight reduction could reduce incident cancer rates. 470 
A recent meta-analysis, involving six observational studies on 51740 subjects 471 
including the largest prospective Swedish Obese Subjects (SOS) study cohort, 472 
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reported a 45% relative risk reduction of cancer in obese subjects after bariatric 473 
surgery (95% CI 0.41 – 0.73; p <0.0001). If stratified by gender, the protective effect 474 
of bariatric surgery was found to be protective in women but not in men. (65) This 475 
might reflect a reduction of sex steroid-related cancer. Nonetheless, several 476 
mechanisms had been postulated to link bariatric surgery with cancer risk reduction, 477 
and one of them was reported to act via modulation of the adipokines. (66) While 478 
adiponectin level was shown to increase for up to 1 year post-operatively, leptin and 479 
resistin levels were shown to decrease significantly up to 2 and 6 years after surgery, 480 
respectively. (66) 481 
 482 
Adipokines remain one of the major players in obesity related carcinogenesis. Both 483 
adipokines and their respective downstream signaling pathways have become novel 484 
targets in cancer therapeutics research. As adiponectin itself is difficult to synthesize, 485 
synthetic small peptides like ADP-355, which can mimic the action of adiponectin, 486 
are being tested in preclinical studies to restrict proliferation of several adiponectin 487 
receptor-positive cancer cell lines. (67) Furthermore, as HMW adiponectin constitutes 488 
the most active oligomeric form of adiponectin, a novel class of non-thiazolidinedione 489 
peroxisome proliferator-activated receptor (PPAR) ligand, AMG131, has been 490 
developed to increase the ratio of high molecular weight to total adiponectin 491 
concentrations in the circulation. (30) Pegylated leptin receptor antagonist 2 (PEG-492 
LPrA2) are also being tested in preclinical studies to reduce the proliferation and 493 
angiogenesis of breast cancer cells. (67) Preclinical studies have shown that 494 
monoclonal antibodies against IL-6 and its receptors can significantly inhibit tumour 495 
growth either alone or in combination with conventional chemotherapy. Among them, 496 
siltuximab, a monoclonal antibody against IL-6, is being evaluated in phase 2 clinical 497 
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trials against transplant-refractory multiple myeloma, hormone-refractory prostate 498 
cancer and metastatic renal cell carcinoma. Besides, results have been promising in 499 
other solid tumours including ovarian and non-small cell lung cancers. Inhibitors 500 
against downstream signaling pathways like JAK or STAT3 inhibitors are also being 501 
studied in phase 1 or 2 clinical trials on advanced solid tumours and haematological 502 
malignancies. (61) 503 
 504 
Although there are emerging data on the association between genetic polymorphisms 505 
of obesity-related genes and cancer susceptibility, there is currently insufficient 506 
evidence to recommend their use as predictors for incident cancer, or as prognostic 507 
biomarkers in those who have developed cancer. Nevertheless, a recent meta-analysis 508 
suggested that the LEP G2548A polymorphism, which had been reported to alter 509 
serum leptin levels, was associated with increased overall cancer risk (Odds ratio 510 
1.27; 95% CI 1.05 – 1.54). (68) However, with regard to adiponectin, no consistent 511 
association has been found between cancer susceptibility and genetic polymorphisms 512 
of either the adiponectin gene (ADIPOQ) or adiponectin receptor genes 513 
(ADIPOR1/R2) in studies on non-Hodgkin’s lymphoma, breast, colorectal and 514 
prostate cancers. Three ADIPOQ single nucleotide polymorphisms (SNPs) had been 515 
reported to be associated with a reduced risk of endometrial cancer in a Chinese 516 
study. However, serum adiponectin level was not measured in that study and whether 517 
these SNPs were biologically relevant remained to be elucidated. (16) Therefore, in 518 
this era of genetics and epigenetics, future research should be directed towards 519 
investigating whether these SNPs can be usefully employed as biomarkers in clinical 520 
oncology practice.  521 
 522 
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Conclusions 523 
With advances in basic and translational research, and assay development, novel 524 
adipokines are continually being found to be implicated in obesity-related 525 
tumourigenesis. Improved understanding of the interplay of adipokines with various 526 
malignancies has unraveled the pathogenic mechanisms underlying the associations 527 
between obesity and cancer, and led to more targeted cancer therapeutics to counter 528 
the increasing challenge posed by obesity-related cancers, consequent to the obesity 529 
epidemic. 530 
 531 
 532 
 533 
 534 
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Figure 1: Schematic diagram showing the interaction of various major adipokines and their downstream 
signaling pathways  
361x270mm (72 x 72 DPI)  
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